U.S. Influenza Diagnostics Market Worth USD 865.4 Million by 2024 | Hexa Research

February 14 14:38 2019

Fact-based market research, penetrating industry insights and validated forecasts to help you make better decisions for a stronger future
Research Report on U.S. Influenza Diagnostics Market Size and Forecast, By Test (RIDT, RT-PCR, Cell Culture), By End-use (Hospitals, Laboratories, Point-of-Care Testing), And Trend Analysis, 2013 – 2024

14 February 2019, The U.S. Influenza Diagnostics Market size is expected to reach USD 865.4 million by 2024. Influenza or flue is an infectious disease and affects the upper respiratory tract in humans. The disease is common in people aged 65 years and above and in children below 5 years of age. Rising demand for faster diagnosis of influenza as a result of growing disease prevalence is expected to foster market growth over the forecast period. In addition, new product developments and technological advancements in healthcare sector are expected to drive the market in the forthcoming years. For instance, in 2014, Lab-in-a-Tube influenza A/B assay was developed by Massachusetts-based IQuum. In addition, BioFire Diagnostics, LLC, developed FilmArray diagnostic system to detect bacteria, viruses, parasites, and yeast. 

Chronic diseases are generally incurable illnesses such as asthma, diabetes, heart disease, and cancer. These diseases are often manageable through early detection, exercise, improved diet, and treatment therapy. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) actively record data related to influenza virus to counter the disease in a systematic manner. Increasing awareness regarding the availability of medical facilities and technological developments are expected to further propel growth of the U.S. influenza diagnostics market over the forecast period. Rapid Influenza Diagnostic Tests (RIDT) accounted for the largest share of the market in 2016. 

These immunoassays and are the most commonly preferred diagnostic tests. RIDTs deliver accurate results in less than 30 minutes. Ease of use and short result turnaround time are the key factors responsible for the growth of this test segment. In addition, chances for negative results are very low in RIDT. This factor is also anticipated to positively influence demand over the forecast period. 

Reverse Transcription Polymerase Chain Reaction (RT-PCR) are influential tests and can determine the influenza virus type A and B. Sharper turnaround time and detailed analytical results are expected to drive the RT-PCR test segment over the forecast period. Cell culture are standard procedures for virus isolation. Precise identification of virus is expected to drive the cell culture segment in the coming years. 

Hospitals segment led the U.S. influenza diagnostics market in 2016. However, Point-of-Care (PoC) testing segment is predicted to be the dominant segment during the forecast years. Efficient work flow process, speed of diagnosis and treatment, expanded testing capabilities, ease of handling, and specimen stability are expected to drive the PoC segment. Moreover, advancements in PoC testing, such as error-free results and shorter turnaround times, are expected to drive the segment further. 

Browse Details of Report @ https://www.hexaresearch.com/research-report/us-influenza-diagnostics-market 

Some of the prominent companies in the U.S. influenza diagnostics market include Alere, Inc.; Becton, Dickinson and Company (BD); Meridian Bioscience, Inc.; Quidel Corporation; Roche Diagnostics Corporation; SA Scientific; Sekisui Diagnostics, LLC; and Thermo Fisher Scientific, Inc. Most companies focus on development of cost-effective and technologically advance devices for effective treatment. For instance, Alere Inc. received clearance from the U.S. Food and Drug Administration (FDA) for Alere i Influenza A & B test. It offers better diagnostic efficiency and effectiveness in identifying the influenza A and B viruses. 

Hexa Research has segmented the U.S. influenza diagnostics market report based on test and end-use 

Segmentation by Test

    • Rapid Influenza Diagnostic Test (RIDT)

    • Reverse Transcription Polymerase Chain Reaction (RT-PCR)

    • Cell Culture

    • Others

 Segmentation by End-use

    • Hospitals

    • Point-of-Care Testing (POCT)

    • Laboratories 

Key Players Analyzed:

    • Alere

    • Becton, Dickinson and Company (BD)

    • Meridian Bioscience, Inc.

    • Quidel Corporation

    • Roche Diagnostics Corporation

    • SA Scientific

    • Sekisui Diagnostics 

Browse Related Category Reports @
Probiotics MarketThe global probiotics market size was valued at USD 38.32 billion in 2016. Increasing prevalence of Irritable Bowel Syndrome (IBS), inflammatory bowel disease, digestive disorders, and dermatitis is expected to drive product consumption 

U.S. Medical Gases MarketU.S. medical gases market size was valued at USD 2,756.8 million in 2016. Increasing use of these gases for the treatment of Cardiovascular Diseases (CVDs) and respiratory illnesses is expected to drive the market over the forecast period 

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. 

More Information Visit @ www.hexaresearch.com

Media Contact
Company Name: Hexa Research
Contact Person: Ryan Shaw
Email: Send Email
Phone: +1-408-342-1548, Toll Free:+1-800-489-3075
Address:Felton Office Plaza, 6265 Highway 9
City: Felton
State: California
Country: United States
Website: www.hexaresearch.com/research-report/us-influenza-diagnostics-market